Abstract:
Disclosed is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Specifically disclosed is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In the formula, Ar represents a furyl group or the like; R
Abstract:
Disclosed is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Specifically disclosed is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and -X-Y represents a diaryl group such as a biphenyl group.)
Abstract:
An apparatus comprising: a sprayer for inoculating a microbe on a first division divided from at least one sample of a plant to be examined; sample leaving device for leaving a second division divided from the sample not inoculated with the microbe and the first division inoculated with the microbe, for a predetermined period of time under a predetermined condition; first and second photodetector for respectively measuring the quantities of luminescence emitted from the first and second divisions which have been left standing by the sample leaving device; and a computer for comparing the quantities of the luminescence measured by the first and second photodetector, thereby to examine the resistance or sensitivity of the plant to the microbe.
Abstract:
An object of the present invention is to provide a method for predicting a risk of developing cancer. DNA samples were prepared from blood and cancer tissues of 2480 cancer patients and analyzed for the nucleotide sequences of exon regions using NGS. As a result, among the cancer patients, 7 patients were confirmed to have D49H mutation or A159D mutation which is a germ cell mutation.
Abstract:
An object is to produce a new anti-B7-H4 antibody having high specificity and affinity and provide a composition for treating cancer making use thereof. A monoclonal antibody that specifically binds to an extracellular domain protein of a human B7-H4 protein is newly produced and an "anti-B7-H4 antibody-effector cell complex" in which the monoclonal antibody and an effector cell are bound in order to enhance the antibody-dependent cellular cytotoxicity of the monoclonal antibody or a bispecific antibody comprising an antigen recognition region of the monoclonal antibody and an effector cell antigen recognition region is further produced and used as a composition for treating cancer.
Abstract:
An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample. The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia according to the present invention as a solution means thereof comprises: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ±(2,3) bond, thereby binding the monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ±(2, 3) bond to the free PSA bound to the anti-free PSA antibody immobilized on the carrier; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an ±(2, 3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determining that when the measured amount is larger than the cutoff value, prostate carcinoma is developed or the probability of developing prostate carcinoma is high, and when the measured amount is smaller than the cutoff value, benign prostatic hyperplasia is developed or the probability of developing benign prostatic hyperplasia is high.
Abstract:
This invention provides a laser marking method that can form a very minute mark of a predetermined shape, such as a letter or pattern, with clarity and high solidity, on the surface of a substrate. The laser marking method of the invention comprises the steps of (1) depositing a coloring material on the surface of a substrate of thermoplastic material to form a thin film of the coloring material, and (2) applying a laser beam to the thin film of the coloring material in conformity with a predetermined marking shape to cause the portions of the substrate irradiated with the laser beam to soften and to cause the thus softened portions to mix with the coloring material, thereby developing the predetermined marking shape on the surface of the substrate.